Novartis AG (NVS) Holdings Lifted by Landmark Bank

Landmark Bank grew its position in Novartis AG (NYSE:NVS) by 4.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,276 shares of the company’s stock after purchasing an additional 188 shares during the period. Landmark Bank’s holdings in Novartis were worth $367,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. IFP Advisors Inc boosted its holdings in shares of Novartis by 4.3% in the fourth quarter. IFP Advisors Inc now owns 11,448 shares of the company’s stock worth $976,000 after buying an additional 477 shares during the period. MACRO Consulting Group acquired a new position in shares of Novartis in the fourth quarter worth about $1,594,000. Physicians Financial Services Inc. boosted its holdings in shares of Novartis by 27.1% in the fourth quarter. Physicians Financial Services Inc. now owns 16,754 shares of the company’s stock worth $1,438,000 after buying an additional 3,575 shares during the period. Somerset Trust Co boosted its holdings in shares of Novartis by 2.5% in the fourth quarter. Somerset Trust Co now owns 15,949 shares of the company’s stock worth $1,369,000 after buying an additional 384 shares during the period. Finally, Lavaca Capital LLC acquired a new stake in shares of Novartis during the fourth quarter worth approximately $48,000. Institutional investors own 11.18% of the company’s stock.

Shares of NVS stock traded down $0.17 during trading on Wednesday, hitting $88.15. 1,933,300 shares of the company were exchanged, compared to its average volume of 1,949,280. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.96 and a current ratio of 1.20. The stock has a market cap of $205.57 billion, a P/E ratio of 18.33, a P/E/G ratio of 1.89 and a beta of 0.73. Novartis AG has a twelve month low of $72.30 and a twelve month high of $94.19.



Several research firms recently commented on NVS. Wolfe Research began coverage on shares of Novartis in a report on Tuesday, October 23rd. They set an “outperform” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a report on Tuesday, November 6th. Guggenheim began coverage on shares of Novartis in a report on Monday, October 8th. They set a “neutral” rating for the company. Barclays cut shares of Novartis from an “equal weight” rating to a “sell” rating in a report on Friday, December 7th. Finally, Cowen upgraded shares of Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 price target for the company in a report on Sunday, December 2nd. Three analysts have rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Novartis presently has an average rating of “Hold” and an average price target of $90.94.

TRADEMARK VIOLATION NOTICE: This article was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://dakotafinancialnews.com/2019/01/24/novartis-ag-nvs-holdings-lifted-by-landmark-bank.html.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Featured Article: Google Finance

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply